Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Bubbly Drinks Inspire More Effective Cancer Treatment

By University of Oxford | June 13, 2016

Oxygen bubbles in fluid Image credit: Vladimir Arndt/ Shutterstock

Researchers at the Universities of Oxford and Ulster, supported by Cancer Research UK, are investigating how to re-oxygenate tumors with a drink that could deliver extra oxygen to the site of the tumour, allowing radiotherapy and chemotherapy to deliver a knock-out blow.

Some tumors have learnt to adapt to harsher, low oxygen conditions making them more resistant to drugs. This is because as tumors grow, the blood vessels delivering essential nutrients, including oxygen, become increasingly twisted and weak meaning chemotherapy fails to penetrate the heart of the tumour.

Scientists are investigating how oxygen bubbles get from the stomach to pancreatic tumors in the laboratory and working out whether this could be done by giving patients the equivalent of a bubbly drink.

The scientists chose pancreatic cancer because these tumors are badly starved of oxygen and so patients have limited treatment options.

Current methods of oxygenating tumors in patients includes breathing pure oxygen, putting patients in oxygen chambers or injecting liquids full of oxygen directly to the tumour site. These are effective but can have quite serious side effects including damage to the surface of the lungs and nervous system.

This new approach could have fewer risks, cost less, and could easily be used to boost other treatments.

Professor Eleanor Stride, Cancer Research UK scientist at the University of Oxford, said: ‘We’re especially excited about the potential this bubbly drink could have for hard to treat cancers like pancreatic cancer, where survival rates are low and better treatments are urgently needed.

‘We’ve had success in the lab in mice, so we’re now looking at how to scale this up for patients.’

Pancreatic cancer is the fifth most common cause of cancer death in the UK, taking the lives of around 8,700 people each year.  Cancer Research UK has made it a priority area and are increasing investment in pancreatic cancer research, citing a need for ‘bold approaches that try something new where things haven’t worked in the past.’

Dr Iain Foulkes, executive director for research funding at Cancer Research UK, said: ‘We’re investing in pioneering ways to improve survival for patients. Prof Stride and her team are thinking outside the box, and this is just the sort of innovation we want to spark through our Pioneer Awards scheme. By being bold we aim to make a difference.’


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE